{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:42:47Z","timestamp":1782992567505,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The Markov model was used in our research. The response rate and relapse rate data were derived from two clinical trials and one retrospective study. Cost and utility values were derived from published literature, a third-party database, and healthcare documents. In addition, one-way sensitivity analysis and probabilistic sensitivity analysis were performed to observe the stability of the model and data source.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In the Markov model, compared with RTX, rhTPO+RTX yielded an additional 0.04 QALYs, with an incremental cost of 2,802 USD. The ICER was 69,097 USD\/QALY. According to the results from the one-way sensitivity analysis, complete response of rhTPO+RTX, utility of complete response and response of RTX were the main drivers in the model. The results from the probabilistic sensitivity analysis demonstrated that there was a 100% probability that rhTPO+RTX was not cost-effective vs. RTX alone at a threshold of $10,805\/QALY and an 84% probability at a threshold of $32,415\/QALY.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> RTX+rhTPO was not more cost-effective than RTX alone as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China.<\/jats:p>","DOI":"10.3389\/fmed.2021.657539","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T07:42:00Z","timestamp":1616053320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China"],"prefix":"10.3389","volume":"8","author":[{"given":"Mingjun","family":"Rui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/MOH.0b013e3282ba5552","article-title":"Pathogenesis of chronic immune thrombocytopenic purpura","volume":"14","author":"Cines","year":"2007","journal-title":"Curr Opin Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00277-010-1087-x","article-title":"Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis","volume":"90","author":"Khellaf","year":"2011","journal-title":"Ann Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1185\/03007990903451298","article-title":"Impact of ITP on physician visits and workplace productivity","volume":"26","author":"Tarantino","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.issn.0253-2727.2020.08.001","article-title":"[Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]","volume":"41","author":"Liu","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood."},{"key":"B11","volume-title":"China Guidelines for Pharmacoeconomics Evaluation 2020 Edition","author":"Liu","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1600-0609.2005.00517.x","article-title":"Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China","volume":"75","author":"Wang","year":"2005","journal-title":"Eur J Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/ajh.25646","article-title":"A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia","volume":"94","author":"Zhou","year":"2019","journal-title":"Am J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1185\/03007995.2010.494126","article-title":"Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura","volume":"26","author":"Szende","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"B15","first-page":"31","article-title":"The cost-effective comparision of laparoscopic splenectomy by two different pedicle division strategy for the treatment of ITP","volume":"23","author":"Liu-Bin","year":"2011","journal-title":"J Hepatopancreatobiliary Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40261-019-00820-6","article-title":"Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China","volume":"39","author":"Chen","year":"2019","journal-title":"Clin Drug Invest."},{"key":"B17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clinthera.2012.01.012","article-title":"Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context","volume":"34","author":"Wu","year":"2012","journal-title":"Clin Therap."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Internal Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.657539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T07:42:03Z","timestamp":1616053323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.657539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":19,"alternative-id":["10.3389\/fmed.2021.657539"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.657539","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"article-number":"657539"}}